Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,897.00    45.00 (1.58%)
Bid:
2,892.00
Ask:
2,894.00
Spread: 2.00 (0.069%)
Market Cap: £4.04b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Completed divestment

1 Jul 2022 07:00

RNS Number : 9187Q
Croda International PLC
01 July 2022
Β 

Stock market announcement

1 July 2022

Completed divestment - transitioning to a pure-play Consumer Care and Life Sciences company

Croda International Plc ('Croda'), which uses smart science to create high performance ingredients and technologies that improve lives, today announces the completion of the divestment of the majority of its Performance Technologies and Industrial Chemicals businesses to a wholly owned subsidiary of Cargill Inc ('Cargill'), as more fully described in Croda's initial announcement on 22 December 2021.

The gross proceeds will be approximately €775m (approximately Β£667m), subject to small, customary adjustments for cash and debt-like instruments, and working capital, in line with the earlier announcement. The divestment and the associated proceeds exclude Croda Sipo ('Sipo'), a Chinese joint venture in which Croda has a 65% shareholding. Croda continues to discuss with its joint venture partner the acquisition of its stake in Sipo, to enable a subsequent sale by Croda to Cargill of 100% of Sipo for €140m.Β 

Steve Foots, Chief Executive of Croda, said: "This divestment accelerates Croda's transition to being a pure-play Consumer Care and Life Sciences company. We will redeploy capital and resources to scale our consumer, health and crop care technologies, helping to deliver consistent, superior sales growth and even stronger profit margins."

Β 

Further information

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

Β 

Advisers to Croda

Β 

Morgan Stanley & Co. International Plc (Financial Adviser & Corporate Broker)

Shirav Patel, Andrew Foster

Centerview Partners (Financial Adviser)

James Hartop

Freshfields Bruckhaus Deringer (Legal Adviser)

Oliver Lazenby

Teneo (Financial PR)

Charlie Armitstead

Β 

Disclaimers

Β 

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA in theΒ UKΒ is acting exclusively as financial adviser and corporate broker to Croda and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

Β 

Centerview Partners UK LLP ("Centerview Partners") is authorised and regulated by the Financial Conduct Authority. Centerview Partners is acting exclusively for Croda and no one else in connection with the matters referred to in this announcement. Centerview Partners is not and will not be responsible to anyone other than Croda for providing the protections afforded to its clients or for providing advice in connection with the contents of this announcement or any other matter referred to in this announcement. Neither Centerview Partners, nor any of its affiliates, owes or accepts any duty, liability or responsibility whatsoever to any person who is not a client of Centerview Partners in connection with this announcement, any statement contained herein or otherwise.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DISFMMRTMTIJBIT
Date   Source Headline
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech
11th Jan 20233:45 pmRNSDirector/PDMR Shareholding
13th Dec 20223:04 pmRNSDirector/PDMR Shareholding
6th Dec 202212:36 pmRNSDirector/PDMR Shareholding
14th Nov 20223:33 pmRNSHolding(s) in Company
11th Nov 20222:04 pmRNSDirector/PDMR Shareholding
11th Nov 202210:37 amRNSDirector/PDMR Shareholding
11th Nov 202210:33 amRNSDirector/PDMR Shareholding
8th Nov 202211:23 amRNSDirector/PDMR Shareholding
7th Nov 20226:11 pmRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.